A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation

Suneel Deepak Kamath*, Xiaoqi Lin, Aparna Kalyan

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The role of next-generation sequencing from either circulating tumor DNA (ctDNA) or formalin-fixed paraffin-embedded (FFPE) tissue to identify therapeutically targetable genomic alterations has been well established. Genomic profiling may also have untapped potential as a diagnostic tool in cases in which traditional immunohistochemistry assays cannot establish a clear histologic diagnosis. Expanding the number of histologies with unique genomic signatures or alterations is critical in this setting. Here we describe a case of a 73-year-old man who presented with a duodenal mass extending to the liver and peritoneal carcinomatosis, initially thought to be metastatic duodenal adenocarcinoma. Subsequent genomic profiling of ctDNA and FFPE tissue revealed an IDH1 mutation, which is rare in duodenal adenocarcinoma but common in biliary tract cancers (BTCs). This finding prompted a second biopsy, which revealed pancreaticobiliary adenocarcinoma. The clinical significance of IDH mutations in terms of their molecular specificity to certain histologies is reviewed. Recent and ongoing investigations into IDH inhibitors for advanced and metastatic BTCs are also discussed. Key Points: This case demonstrates a novel use of next-generation sequencing as a diagnostic tool to modify a primary cancer diagnosis, leading to important changes in therapy. Isocitrate dehydrogenase mutations are rare in solid organ malignancies and are highly specific for biliary tract cancers (BTCs) within the gastrointestinal malignancies. IDH inhibition is an active area of investigation in metastatic BTCs; early results have been promising.

Original languageEnglish (US)
Pages (from-to)151-156
Number of pages6
JournalOncologist
Volume24
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Biliary Tract Neoplasms
Mutation
Adenocarcinoma
Neoplasms
Paraffin
Formaldehyde
Histology
Isocitrate Dehydrogenase
DNA
Immunohistochemistry
Carcinoma
Biopsy
Liver

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{c13815cb1f054333b0595bb7720c6a17,
title = "A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation",
abstract = "The role of next-generation sequencing from either circulating tumor DNA (ctDNA) or formalin-fixed paraffin-embedded (FFPE) tissue to identify therapeutically targetable genomic alterations has been well established. Genomic profiling may also have untapped potential as a diagnostic tool in cases in which traditional immunohistochemistry assays cannot establish a clear histologic diagnosis. Expanding the number of histologies with unique genomic signatures or alterations is critical in this setting. Here we describe a case of a 73-year-old man who presented with a duodenal mass extending to the liver and peritoneal carcinomatosis, initially thought to be metastatic duodenal adenocarcinoma. Subsequent genomic profiling of ctDNA and FFPE tissue revealed an IDH1 mutation, which is rare in duodenal adenocarcinoma but common in biliary tract cancers (BTCs). This finding prompted a second biopsy, which revealed pancreaticobiliary adenocarcinoma. The clinical significance of IDH mutations in terms of their molecular specificity to certain histologies is reviewed. Recent and ongoing investigations into IDH inhibitors for advanced and metastatic BTCs are also discussed. Key Points: This case demonstrates a novel use of next-generation sequencing as a diagnostic tool to modify a primary cancer diagnosis, leading to important changes in therapy. Isocitrate dehydrogenase mutations are rare in solid organ malignancies and are highly specific for biliary tract cancers (BTCs) within the gastrointestinal malignancies. IDH inhibition is an active area of investigation in metastatic BTCs; early results have been promising.",
author = "Kamath, {Suneel Deepak} and Xiaoqi Lin and Aparna Kalyan",
year = "2019",
month = "2",
day = "1",
doi = "10.1634/theoncologist.2018-0210",
language = "English (US)",
volume = "24",
pages = "151--156",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "2",

}

A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation. / Kamath, Suneel Deepak; Lin, Xiaoqi; Kalyan, Aparna.

In: Oncologist, Vol. 24, No. 2, 01.02.2019, p. 151-156.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation

AU - Kamath, Suneel Deepak

AU - Lin, Xiaoqi

AU - Kalyan, Aparna

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The role of next-generation sequencing from either circulating tumor DNA (ctDNA) or formalin-fixed paraffin-embedded (FFPE) tissue to identify therapeutically targetable genomic alterations has been well established. Genomic profiling may also have untapped potential as a diagnostic tool in cases in which traditional immunohistochemistry assays cannot establish a clear histologic diagnosis. Expanding the number of histologies with unique genomic signatures or alterations is critical in this setting. Here we describe a case of a 73-year-old man who presented with a duodenal mass extending to the liver and peritoneal carcinomatosis, initially thought to be metastatic duodenal adenocarcinoma. Subsequent genomic profiling of ctDNA and FFPE tissue revealed an IDH1 mutation, which is rare in duodenal adenocarcinoma but common in biliary tract cancers (BTCs). This finding prompted a second biopsy, which revealed pancreaticobiliary adenocarcinoma. The clinical significance of IDH mutations in terms of their molecular specificity to certain histologies is reviewed. Recent and ongoing investigations into IDH inhibitors for advanced and metastatic BTCs are also discussed. Key Points: This case demonstrates a novel use of next-generation sequencing as a diagnostic tool to modify a primary cancer diagnosis, leading to important changes in therapy. Isocitrate dehydrogenase mutations are rare in solid organ malignancies and are highly specific for biliary tract cancers (BTCs) within the gastrointestinal malignancies. IDH inhibition is an active area of investigation in metastatic BTCs; early results have been promising.

AB - The role of next-generation sequencing from either circulating tumor DNA (ctDNA) or formalin-fixed paraffin-embedded (FFPE) tissue to identify therapeutically targetable genomic alterations has been well established. Genomic profiling may also have untapped potential as a diagnostic tool in cases in which traditional immunohistochemistry assays cannot establish a clear histologic diagnosis. Expanding the number of histologies with unique genomic signatures or alterations is critical in this setting. Here we describe a case of a 73-year-old man who presented with a duodenal mass extending to the liver and peritoneal carcinomatosis, initially thought to be metastatic duodenal adenocarcinoma. Subsequent genomic profiling of ctDNA and FFPE tissue revealed an IDH1 mutation, which is rare in duodenal adenocarcinoma but common in biliary tract cancers (BTCs). This finding prompted a second biopsy, which revealed pancreaticobiliary adenocarcinoma. The clinical significance of IDH mutations in terms of their molecular specificity to certain histologies is reviewed. Recent and ongoing investigations into IDH inhibitors for advanced and metastatic BTCs are also discussed. Key Points: This case demonstrates a novel use of next-generation sequencing as a diagnostic tool to modify a primary cancer diagnosis, leading to important changes in therapy. Isocitrate dehydrogenase mutations are rare in solid organ malignancies and are highly specific for biliary tract cancers (BTCs) within the gastrointestinal malignancies. IDH inhibition is an active area of investigation in metastatic BTCs; early results have been promising.

UR - http://www.scopus.com/inward/record.url?scp=85055432418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055432418&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2018-0210

DO - 10.1634/theoncologist.2018-0210

M3 - Article

VL - 24

SP - 151

EP - 156

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 2

ER -